Early beta-blocker-carbonic anhydrase inhibitor fixed combination use after Ahmed glaucoma valve implantation


Un Y., Imamoglu S., Alpogan O., TURAN-VURAL E., Unculu R. B.

European eye research, cilt.5, sa.1, ss.9-16, 2025 (TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.14744/eer.2024.47560
  • Dergi Adı: European eye research
  • Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.9-16
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: Ahmed glaucoma valve (AGV) implantation is an effective surgical option for glaucoma. However, subconjunctival fibrosis is a limiting factor that decreases surgical success. It has been proposed that introducing aqueous suppressants (AS) in the early post-operative period may reduce subconjunctival inflammatory mediators and fibrotic reactions. Starting AS early, before intraocular pressure (IOP) rises, may reduce plate fibrosis and improve post-operative surgical outcomes. The objective of this study was to evaluate the effect of the early introduction of a timolol and carbonic anhydrase inhibitor (TCAI) fixed combination, a commonly used AS drug, on the outcomes of AGV implantation. Methods: This study included all eyes that underwent AGV implant surgery between 2017 and 2022. Eyes that received TCAI within the first 2 post-operative weeks to reduce IOP or control subconjunctival fibrosis around the plate were included in Group 1. Group 2 consisted of eyes in which antiglaucoma medications were introduced stepwise only when IOP increased during follow-up visits after the first 2 post-operative weeks. Patients who received antiglaucomatous drugs other than TCAI within the first 2 post-operative weeks were excluded. Follow-up data were analyzed and compared between the two groups in terms of IOP control and surgical success. Results: IOP decreased from 36.8±10.3 mmHg and 37.5±12.0 mmHg to 13.5±5.49 mmHg and 14.5±6.47 mmHg at the last visit in Groups 1 and 2, respectively (p<0.001 for both). Surgical success at the last visit was 86.1% in Group 1 and 78.2% in Group 2 (p>0.05). The median number of needling procedures showed a significant difference between the groups: 0 (range, 0–2) in Group 1 and 1 in Group 2 (range, 0–4) (p<0.05). Although TCAI therapy was initiated when IOP was >10 mmHg in Group 1, no hypotony-related complications were observed in this group. Conclusion: Initiating TCAI in the early post-operative period after AGV implantation has a beneficial effect in reducing the need for needling procedures.